• Something wrong with this record ?

Relevance of the theoretical critical pore radius in mesoporous silica for fast crystallizing drugs

B. Vraníková, A. Niederquell, Z. Šklubalová, M. Kuentz

. 2020 ; 591 (-) : 120019. [pub] 20201026

Language English Country Netherlands

Document type Journal Article

Formulation of poorly water-soluble drugs with mesoporous silica has become a thriving field of pharmaceutics. The theoretical critical pore diameter has been introduced as a maximum value below which an undesired drug crystallization is suppressed by spatial confinement. Currently, only few values have been reported and study of fast crystallising drugs is missing especially at relevant storage temperatures. This study investigated the critical pore diameter of three model drugs with a poor glass-forming ability (i.e. haloperidol, carbamazepine and benzamide) using different mesoporous carriers (Parteck® SLC 500, Neusilin® US2, Syloid® XDP 3050 and Aeroperl® 300 Pharma) and subsequently monitored physical formulation stability over three months by X-ray powder diffraction. The selected drugs showed clear differences in their estimated critical pore diameters, whereas a temperature dependence was barely relevant for pharmaceutical storage conditions. Superior stability was noted for the formulations containing benzamide in line with its predicted relatively large critical pore diameter of 29.5 nm. Contrarily, impaired physical stability depending on drug loading was observed in the case of haloperidol representing a compound with a rather small critical pore diameter (8.4 nm). These findings confirm the importance of estimating the critical pore diameter, especially for poor glass-forming drugs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019650
003      
CZ-PrNML
005      
20210830101231.0
007      
ta
008      
210728s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijpharm.2020.120019 $2 doi
035    __
$a (PubMed)33122108
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Vraníková, Barbora $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; Institute for Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences FHNW, Hofackerstr. 30, 4132 Muttenz, Switzerland. Electronic address: vranikovab@faf.cuni.cz
245    10
$a Relevance of the theoretical critical pore radius in mesoporous silica for fast crystallizing drugs / $c B. Vraníková, A. Niederquell, Z. Šklubalová, M. Kuentz
520    9_
$a Formulation of poorly water-soluble drugs with mesoporous silica has become a thriving field of pharmaceutics. The theoretical critical pore diameter has been introduced as a maximum value below which an undesired drug crystallization is suppressed by spatial confinement. Currently, only few values have been reported and study of fast crystallising drugs is missing especially at relevant storage temperatures. This study investigated the critical pore diameter of three model drugs with a poor glass-forming ability (i.e. haloperidol, carbamazepine and benzamide) using different mesoporous carriers (Parteck® SLC 500, Neusilin® US2, Syloid® XDP 3050 and Aeroperl® 300 Pharma) and subsequently monitored physical formulation stability over three months by X-ray powder diffraction. The selected drugs showed clear differences in their estimated critical pore diameters, whereas a temperature dependence was barely relevant for pharmaceutical storage conditions. Superior stability was noted for the formulations containing benzamide in line with its predicted relatively large critical pore diameter of 29.5 nm. Contrarily, impaired physical stability depending on drug loading was observed in the case of haloperidol representing a compound with a rather small critical pore diameter (8.4 nm). These findings confirm the importance of estimating the critical pore diameter, especially for poor glass-forming drugs.
650    _2
$a poréznost $7 D016062
650    _2
$a prášky, zásypy, pudry $7 D011208
650    12
$a radius $7 D011884
650    12
$a oxid křemičitý $7 D012822
650    _2
$a rozpustnost $7 D012995
650    _2
$a difrakce rentgenového záření $7 D014961
655    _2
$a časopisecké články $7 D016428
700    1_
$a Niederquell, Andreas $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; Institute for Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences FHNW, Hofackerstr. 30, 4132 Muttenz, Switzerland. Electronic address: andreas.niederquell@fhnw.ch
700    1_
$a Šklubalová, Zdenka $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. Electronic address: sklubalova@faf.cuni.cz
700    1_
$a Kuentz, Martin $u Institute for Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences FHNW, Hofackerstr. 30, 4132 Muttenz, Switzerland. Electronic address: martin.kuentz@fhnw.ch
773    0_
$w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 591, č. - (2020), s. 120019
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33122108 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101231 $b ABA008
999    __
$a ok $b bmc $g 1690461 $s 1140096
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 591 $c - $d 120019 $e 20201026 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...